Dr. Liebowitz is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
14 East 90th St
Suite 1a
New York, NY 10128Phone+1 212-876-9881Fax+1 212-876-6148
Education & Training
- New York Presbyterian Hospital (Columbia Campus)/New York State Psychiatric InstituteResidency, Psychiatry, 1975 - 1977
- University of Vermont Medical CenterResidency, Psychiatry, 1974 - 1975
- Harlem Hospital CenterResidency, Internal Medicine, 1969 - 1971
- Yale School of MedicineClass of 1969
Certifications & Licensure
- NY State Medical License 1970 - 2026
- NJ State Medical License 1977 - 2025
- American Board of Psychiatry and Neurology Psychiatry
Clinical Trials
- Cognitive Behavioral Therapy Plus Drug Treatment for Obsessive Compulsive Disorder Start of enrollment: 2000 Aug 01
- Adding Cognitive Behavioral Therapy to Drug Treatment for Social Anxiety Disorder Start of enrollment: 2003 Dec 01
- Add-On Study of MSI-195 (S-Adenosyl-L-Methionine, SAMe) for Patients With Major Depressive Disorder (MDD) Start of enrollment: 2013 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- 4 citationsEfficacy, safety, and tolerability of nivasorexant in adults with binge-eating disorder: A randomized, Phase II proof of concept trial.Susan L McElroy, Preciosa M Coloma, Benjamin Berger, Anna I Guerdjikova, J Mark Joyce
The International Journal of Eating Disorders. 2023-11-01 - 5 citationsEfficacy, Safety, and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder: Results of 2 Phase 3, Randomized...Lenard A Adler, Julie Adams, Jessica Madera-McDonough, Eva Kohegyi, Mary Hobart
Journal of Clinical Psychopharmacology. 2022-06-02 - 52 citationsThe effects of inhibition of fatty acid amide hydrolase (FAAH) by JNJ-42165279 in social anxiety disorder: a double-blind, randomized, placebo-controlled proof-of-conc...Mark E. Schmidt, Michael R. Liebowitz, Murray B. Stein, Jennifer Grunfeld, Ilse Van Hove
Neuropsychopharmacology. 2021-04-01
Press Mentions
- VistaGen Therapeutics Announces Positive Meeting with FDA Regarding Pivotal Phase 3 Study of PH94BJuly 23rd, 2020
- VistaGen Therapeutics Reports Fiscal Year 2020 Results and Provides CNS Pipeline UpdateJune 29th, 2020
- Anxiety Disorders: Living on a Thin LineJune 5th, 2005
- Join now to see all
Grant Support
- CBT Augmentation Of Paroxetine For Social AnxietyNational Institute Of Mental Health2003–2006
- CBT Augmentation Of SRI Pharmacotherapy For OCDNational Institute Of Mental Health2000–2004
- Pharmacotherapy Of Social PhobiaNational Institute Of Mental Health1985–2001
- Long Term Treatment Of Social PhobiaNational Institute Of Mental Health1996–2000
- Clomipramine And Behavior Therapy In OCDNational Institute Of Mental Health1997–1999
- Pharmacotherapy Of Social PhobiaNational Institute Of Mental Health1995–1999
- Residual Impairment In Treated OCD PatientsNational Institute Of Mental Health1998
- Chlorimipramine And Behavior Therapy For OCDNational Institute Of Mental Health1992–1993
- Fluoxetine In Adolescent Obsessive Compulsive DisorderNational Institute Of Mental Health1990–1992
- Chlorimipramine And Behavior Therapy For OCDNational Institute Of Mental Health1990–1991
- Psychobiology Of Obsessive-Compulsive DisorderNational Institute Of Mental Health1989–1991
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: